Audio presentations and a core slide library with comprehensive notes, plus ready-to-go presentations.
Ready-to-go Meeting Presentations
Therapeutic algorithms for Crohn’s disease: Where are we in 2012?
Brian G. Feagan, MD
- Potential novel therapies - what's in the pipeline (AMA)
Jean-Frédéric Colombel, MD - Audio
Presentation: Discuss the role of the specialist gastroenterology nurse in answering frequently
posed questions raised by IBD patients
Laurie Powers, RN - Long-term
maintenance of clinical response with biologic treatments
Stephen Hanauer, MD
View
all CME active Slide Libraries
Archive
(CME-expired materials)
Interactive case scenarios providing best practice solutions to common clinical issues.
Pediatric inflammatory bowel disease: Making a timely diagnosis and instituting effective therapy
Joel R. Rosh, MD, FAAP, FACG, AGAF- Approaches to the
long-term management of ulcerative colitis: Optimizing therapeutic choices and patient outcomes
Bret Lashner, MD
- How
can I maximize compliance in my IBD patients?
Sunanda Kane, MD, MSPH, FACG, FACP, AGAF
- What
can I tell my patients to expect in terms of patient reported outcomes and quality-of-life
with biologic therapies for IBD?
Ashwin N. Ananthakrishnan, MD, MPH
View
all CME active Curbside Consults and Clinical Decision Maps
Expert commentary based on the latest published data with downloadable PowerPoint slides illustrating the key information.
IBS and IBD: Similar beginnings, but different endings?
Brian E. Lacy, PhD, MD- Recent advances in the management of mildly-to-moderately active ulcerative colitis
Bret A. Lashner, MD - The
use of prognostic markers to determine disease course and to improve management
Mark Silverberg, MD - Viral hepatitis and IBD: Recommendations for vaccination and treatment therapy in IBD (AMA)
Gil Y. Melmed, MD, MS
- The role of the nurse practitioner in
IBD
Sharon Dudley-Brown, PhD FNP-BC
Please provide us with your comments and feedback about this site.
Expert critiques of the most important recent publications in IBD.
Summarized by A. Hillary Steinhart, MD, MSc, FRCP(C)
This section is eligible for 0.75 AMA PRA Category 1 Credit(s). Please read all articles in the section before applying for CME credits.
- Schnitzler F, Fidder H, Ferrante M, et al. Outcome of pregnancy in women with inflammatory bowel disease treated with antitumor necrosis factor therapy.
- Ogata H, Kato J, Hirai F, et al. Double-blind, placebo-controlled trial of oral tacrolimus (FK506) in the management of hospitalized patients with steroid-refractory ulcerative colitis.
- Meucci G, Fasoli R, Saibeni S, et al, on behalf of the IG-IBD. Prognostic significance of endoscopic remission in patients with active ulcerative colitis treated with oral and topical mesalazine: A prospective, multicenter study.
- Hoivik ML, Moum B, Solberg IC, et al, for the IBSEN Study Group. Health-related quality-of-life in patients with ulcerative colitis after a 10-year disease course: Results from the IBSEN study.
Summarized by Themistocles Dassopoulos, MD
This section is eligible for 0.75 AMA PRA Category 1 Credit(s). Please read all articles in the section before applying for CME credits.
- Yanai H, Hanauer SB. Assessing response and loss of response to biological therapies in IBD.
- 5-aminosalicylate is not chemoprophylactic for colorectal cancer in IBD: A population based study.
- Leblanc S, Allez M, Seksik P, et al. GETAID. Successive treatment with cyclosporine and infliximab in steroid-refractory ulcerative colitis.
- Yarur AJ, Deshpande AR, Pechman DM, et al. Inflammatory bowel disease is associated with an increased incidence of cardiovascular events.
- Toedter G, Li K, Marano C, et al. Gene expression profiling and response signatures associated with differential responses to infliximab treatment in ulcerative colitis.
